Cediranib | AZD2171;ZD 2171;NSC-732208 | VEGFR | AmBeed-信号通路专用抑制剂

首页 / / / VEGFR / Cediranib

西地尼布 /Cediranib {[allProObj[0].p_purity_real_show]}

货号：A368855 同义名： AZD2171;ZD 2171

Cediranib is a multiple RTKs inhibitor with IC50 values of <0.001μM, 0.005μM, ≤0.003μM, 0.002μM and 0.005μM for VEGFR-2, VEGFR-1, VEGFR-3, c-Kit and PDGFR-β(measured kinase activity), respectively.

Cediranib 化学结构
CAS号：288383-20-0

Cediranib 3D分子结构
CAS号：288383-20-0

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Cediranib 纯度/质量文件产品仅供科研

货号：A368855 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell, 2024, 101755. Ambeed. [ A399663 ]; • EMBO J., 2024. Ambeed. [ A295334 ]; • JMC, 2024, 67(20): 18265-18289. Ambeed. [ A538667 , A341145 , A117430 , A172297 ]; • JMC, 2024. Ambeed. [ A210558 , A1518164 ]; • Cell Death Discov., 2024, 10, 436. Ambeed. [ A384235 ]; 更多 >

VEGFR 亚型比较

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2, IC50: 3 nM VEGFR2/Flk1, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	PDGFR,RET	98%
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ VEGFR2, IC50: 25 nM Flk1, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	FGFR,PDGFR,c-Kit	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Kit,c-Fms	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	c-Kit,BTK	98%
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ mVEGF2, IC50: 165 nM hVEGFR2, IC50: 9 nM	+ hVEGFR3, IC50: 420 nM		98%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			98%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	98+%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Rivoceranib Mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	98%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2, IC50: 90 nM VEGFR2/Flk1, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			98%
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	98%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	FLT3,RET	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Cediranib 生物活性

靶点	VEGFR1 VEGFR1/FLT1, IC50:5 nM VEGFR3 VEGFR3/FLT4, IC50:<=3 nM VEGFR2 VEGFR2/KDR, IC50:0.5 nM
描述	VEGF/VEGFR (vascular endothelial growth factor vascular endothelial growth factor receptor) pathway plays a key role in tumor angiogenesis by promotion of vascular and lymphatic endothelial, as well as survival, and invasion, thus resulting in neovascularization, tumor growth and metastasis. In addition, blockade of additional proangiogenic receptor tyrosine kinases, including PDGFR and FGFR, may improve long-term clinical outcomes. Cediranib is a multiple RTKs inhibitor with IC50 values of <0.001μM, 0.005μM, ≤0.003μM, 0.002μM and 0.005μM for VEGFR-2, VEGFR-1, VEGFR-3, c-Kit and PDGFR-β(measured kinase activity), respectively, less potent to PDGFR-α, CSF-1R, FGFR1, Src and Abl with IC50 values of 0.036nM, 0.11nM, 0.026nM, 0.13nM and 0.26nM, respectively. The kinase activity inhibition by Cediranib can be observed through the suppression of phosphorylation on KDR (HUVEC), c-Kit (NCI-H526), PDGFR-α (MG63), PDGFR-β (MG63), CSF-1R (NIH3T3/CSF1R) and EGFR (KB) with IC50 values of 0.0005, 0.001, 0.005, 0.008, 0.21 and 1.1μM, respectively, in cellular study. Consistent with its selectivity on VEGFR, Cediranib inhibited VEGF-stimulated HUVEC proliferation most potently with IC50 value of 0.4nM, versus IC50 values of 110nM/500nM for bFGF-/EGF-induced HUVEC proliferation, as well as 40nM PDGF-induced MG63 proliferation. Also through the inhibition of VEGFR, Cediranib inhibited vessel branching, length, and area with mean IC50 values of 0.1nM, 0.1nM and 0.2nM in in vitro study, as well as completely abolished VEGF-driven angiogenesis at 6mg/kg/day in in vivo models. The effect of Cediranib-induced hypertrophy in bone growth plate and inhibition on luteal development in ovary (5mg/kg, orally) further confirmed its inactivation of VEGF-induced angiogenesis within complex physiologic settings. Cediranib showed broad-spectrum anti-tumor activity as oral administration of Cediranib at dose of 1.5,3 and 6mg/kg once daily inhibited growth of all human tumor xenografts examined, including SW620 (colon), Calu-6 (lung), PC-3 (prostate), MDA-MB-231 (breast) and SKOV-3 (ovary), with vascular regression observed in Calu-6 lung tumor xenografts at dose of 6mg/kg[1].
作用机制	Cediranib is an ATP-competitive inhibitor of KDR tyrosine kinase.[1]

Cediranib 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
HUVEC cell		Proliferation assay	3 days	Inhibition of VEGF-stimulated HUVEC cell proliferation treated before 2 hrs of VEGF challenge assessed after 3 days by [3H]thymidine incorporation assay, ED50=12 nM	19101155

Cediranib 动物研究

Dose	Mice: 1.5 mg/kg, 3 mg/kg^[1] (p.o.), 1 mg/kg - 25 mg/kg^[2] (p.o.); 0.75 mg/kg - 5 mg/kg^[3] (i.p.)
Administration	p.o., i.p.

Cediranib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00691730	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Not Applicable	Active, not recruiting	December 2018	Canada, Alberta ... 展开 >> Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 Canada, Ontario London Regional Cancer Program London, Ontario, Canada, N6A 4L6 Mount Sinai Hospital Toronto, Ontario, Canada, M5G 1X5 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00310089	Breast Cancer	Not Applicable	Completed	-	United States, Maryland ... 展开 >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 United States, New Jersey Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey, United States, 08903 收起 <<
NCT02910843	Rectal Cancer	Phase 1	Recruiting	December 2022	Switzerland ... 展开 >> St. Claraspital Basel Recruiting Basel, Switzerland, 4016 Contact: Dieter Köberle, MD +41 61 685 85 85 dieter.koeberle@claraspital.ch Principal Investigator: Dieter Köberle, MD Universitätsspital Basel Recruiting Basel, Switzerland, 4031 Contact: Viviane Hess, Prof +41 61 265 50 74 viviane.hess@usb.ch Principal Investigator: Viviane Hess, Prof Inselspital Bern Recruiting Bern, Switzerland, 3010 Contact: Martin D. Berger, MD +41 31 632 41 14 martin.berger@insel.ch Principal Investigator: Martin D. Berger, MD Kantonsspital Graubünden Recruiting Chur, Switzerland, 7000 Contact: Ioannis Metaxas, MD +41 81 256 66 46 ioannis.metaxas@ksgr.ch Principal Investigator: Ioannis Metaxas, MD Kantonsspital Luzern Recruiting Luzern, Switzerland, 6000 Contact: Ralph Winterhalder, MD +41 41 205 58 75 ralph.winterhalder@ksl.ch Principal Investigator: Ralph Winterhalder, MD Kantonsspital St. Gallen Recruiting St. Gallen, Switzerland, 9007 Contact: Markus Jörger, MD +41 71 494 29 22 markus.joerger@kssg.ch Principal Investigator: Markus Jörger, MD UniversitätsSpital Zürich Recruiting Zurich, Switzerland, 8091 Contact: Bernhard Pestalozzi, Prof +41 (0)44 255 34 40 bernhard.pestalozzi@usz.ch Principal Investigator: Bernhard Pestalozzi, Prof 收起 <<

Cediranib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.22mL

0.44mL

0.22mL

11.10mL

2.22mL

1.11mL

22.20mL

4.44mL

2.22mL

Cediranib 技术信息

CAS号	288383-20-0
分子式	C₂₅H₂₇FN₄O₃
分子量	450.505

别名	AZD2171;ZD 2171;NSC-732208
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,Store in freezer, under -20°C

溶解度

DMSO: 18 mg/mL(39.96 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00691730	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Not Applicable	Active, not recruiting	December 2018	Canada, Alberta ... 展开 >> Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 Canada, Ontario London Regional Cancer Program London, Ontario, Canada, N6A 4L6 Mount Sinai Hospital Toronto, Ontario, Canada, M5G 1X5 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00310089	Breast Cancer	Not Applicable	Completed	-	United States, Maryland ... 展开 >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 United States, New Jersey Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey, United States, 08903 收起 <<
NCT02910843	Rectal Cancer	Phase 1	Recruiting	December 2022	Switzerland ... 展开 >> St. Claraspital Basel Recruiting Basel, Switzerland, 4016 Contact: Dieter Köberle, MD +41 61 685 85 85 dieter.koeberle@claraspital.ch Principal Investigator: Dieter Köberle, MD Universitätsspital Basel Recruiting Basel, Switzerland, 4031 Contact: Viviane Hess, Prof +41 61 265 50 74 viviane.hess@usb.ch Principal Investigator: Viviane Hess, Prof Inselspital Bern Recruiting Bern, Switzerland, 3010 Contact: Martin D. Berger, MD +41 31 632 41 14 martin.berger@insel.ch Principal Investigator: Martin D. Berger, MD Kantonsspital Graubünden Recruiting Chur, Switzerland, 7000 Contact: Ioannis Metaxas, MD +41 81 256 66 46 ioannis.metaxas@ksgr.ch Principal Investigator: Ioannis Metaxas, MD Kantonsspital Luzern Recruiting Luzern, Switzerland, 6000 Contact: Ralph Winterhalder, MD +41 41 205 58 75 ralph.winterhalder@ksl.ch Principal Investigator: Ralph Winterhalder, MD Kantonsspital St. Gallen Recruiting St. Gallen, Switzerland, 9007 Contact: Markus Jörger, MD +41 71 494 29 22 markus.joerger@kssg.ch Principal Investigator: Markus Jörger, MD UniversitätsSpital Zürich Recruiting Zurich, Switzerland, 8091 Contact: Bernhard Pestalozzi, Prof +41 (0)44 255 34 40 bernhard.pestalozzi@usz.ch Principal Investigator: Bernhard Pestalozzi, Prof 收起 <<
NCT03699449	Platinum-resistant Recurrent O... 展开 >>varian Cancer 收起 <<	Phase 2	Recruiting	September 2022	Korea, Republic of ... 展开 >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 03080 Contact: Jae-Woen Kim, MD, Ph.D +82-2-2072-3511 kjwksh@snu.ac.kr Principal Investigator: Jae-Woen Kim, MD, Ph.D Yonsei University Health System, Severance Hospital Recruiting Seoul, Korea, Republic of, 03722 Contact: Jung-Yun Lee 82-2-2228-2230 jungyunlee@yuhs.ac Samsung Medical Center Recruiting Seoul, Korea, Republic of, 06351 Contact: Byoung-Gie Kim, MD, Ph.D 82-2-3410-3513 bgkim@skku.edu Principal Investigator: Byoung-Gie Kim, MD, Ph.D 收起 <<
NCT00343408	Colorectal Cancer ... 展开 >> Lung Cancer 收起 <<	Phase 1	Completed	-	Canada, Ontario ... 展开 >> Ottawa Hospital Regional Cancer Centre - General Campus Ottawa, Ontario, Canada, K1H 8L6 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Jewish General Hospital - Montreal Montreal, Quebec, Canada, H3T 1E2 收起 <<
NCT00278889	Colorectal Cancer	Phase 2	Completed	-	-
NCT02855697	Ovarian Cancer	Early Phase 1	Recruiting	December 2020	United Kingdom ... 展开 >> The Christie NHS Foundation Trust Recruiting Manchester, United Kingdom, M20 4BX Contact: Andrew Clamp, MD, PhD 0161 446 3606 Andrew.Clamp@christie.nhs.uk Contact: Catherine Rogers, Nurse 0161 918 7689 catherine.rogers@christie.nhs.uk Principal Investigator: Andrew Clamp 收起 <<
NCT03741426	Renal Cell Cancer	Phase 2	Not yet recruiting	April 25, 2022	United Kingdom ... 展开 >> Addenbrooke's Hospital Cambridge, England, United Kingdom, CB2 2QQ 收起 <<
NCT00107250	Colorectal Cancer ... 展开 >> Lung Cancer Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	Canada, Ontario ... 展开 >> Ottawa Hospital Regional Cancer Centre - General Campus Ottawa, Ontario, Canada, K1H 8L6 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00326599	-		Completed	-	-
NCT00278889	-		Completed	-	-
NCT00384176	Colorectal Cancer	Phase 2 Phase 3	Completed	-	-
NCT00326599	Lung Cancer	Phase 2	Completed	-	-
NCT00384176	-		Completed	-	-
NCT01229930	Cervical Cancer	Phase 2	Completed	-	United Kingdom ... 展开 >> Leicester Royal Infirmary Leicester, England, United Kingdom, LE19 4LF Cancer Research UK and University College London Cancer Trials Centre London, England, United Kingdom, W1T 4TJ Christie Hospital Manchester, England, United Kingdom, M20 4BX Royal Marsden - Surrey Sutton, England, United Kingdom, SM2 5PG Edinburgh Cancer Centre at Western General Hospital Edinburgh, Scotland, United Kingdom, EH4 2XR 收起 <<
NCT00454805	Advanced Breast Cancer	Phase 2	Completed	-	United States, California ... 展开 >> Research Site Burbank, California, United States Research Site Los Angeles, California, United States Research Site Palm Springs, California, United States United States, Florida Research Site Boca Raton, Florida, United States United States, Hawaii Research Site Honolulu, Hawaii, United States United States, New York Research Site New York, New York, United States Australia Research Site Fitzroy, Australia Research Site Parkville, Australia Research Site Perth, Australia Research Site Waratah, Australia Brazil Research Site Belo Horizonte, Brazil Research Site Curitiba, Brazil Research Site Fortaleza, Brazil Research Site Porto Alegre, Brazil Research Site Santro Andre, Brazil Research Site São Paulo, Brazil 收起 <<
NCT00502385	Leukaemia Mye... 展开 >>locytic Acute 收起 <<	Phase 1	Completed	-	-
NCT00245154	Lung Cancer	Phase 2 Phase 3	Completed	-	Argentina ... 展开 >> Instituto Alexander Fleming Buenos Aires, Argentina, 1426 Compleso Medico de la Policia Federal Argentina Buenos Aires, Argentina, 1437 Hospital Universitario Austral Buenos Aires, Argentina, B1629AHJ Australia Alfred Hospital Melbourne, Australia, 3004 Brazil Instituto Nacional de Cancer (INCA) Rio de Janeiro, Brazil, CEP20231-050 Canada, Alberta Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 Ottawa Health Research Institute - General Division Ottawa, Ontario, Canada, K1H 8L6 Algoma District Cancer Program Sault Ste. Marie, Ontario, Canada, P6B 0A8 Niagara Health System St. Catharines, Ontario, Canada, L2R 7C6 Northeast Cancer Center Health Sciences Sudbury, Ontario, Canada, P3E 5J1 Mount Sinai Hospital Toronto, Ontario, Canada, M5G 1X5 Univ. Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada University Institute of Cardiology and Quebec, Canada, G1V 4G5 Romania Oncology Institute Bucharest Bucharest, Romania Oncological Institute "Ion Chiricuta" Cluj-Napoca, Romania, 3400 Clinical County Hospital of Sibiu Sibiu, Romania, 2400 Singapore National University Hospital Singapore, Singapore, 119074 收起 <<
NCT00502567	Advanced Solid Tumor	Phase 1	Completed	-	United States, Michigan ... 展开 >> Research Site Ann Arbor, Michigan, United States Research Site Detroit, Michigan, United States United States, Tennessee Research Site Nashville, Tennessee, United States 收起 <<
NCT02502266	Deleterious BRCA1 Gene Mutatio... 展开 >>n Deleterious BRCA2 Gene Mutation Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Fallopian Tube Undifferentiated Carcinoma Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Adenocarcinoma Ovarian Transitional Cell Carcinoma Ovarian Undifferentiated Carcinoma Primary Peritoneal Serous Adenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma 收起 <<	Phase 2 Phase 3	Suspended(Scheduled Interim Mo... 展开 >>nitoring) 收起 <<	-	-
NCT00321581	Refractory or Recurrent Solid ... 展开 >>Tumors Acute Myelogenous Leukemia 收起 <<	Phase 1	Completed	-	United States, Pennsylvania ... 展开 >> Childrens Hospital, Philadelphia Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT00527124	Adenocarcinoma of the Prostate... 展开 >> Stage IV Prostate Cancer 收起 <<	Phase 2	Terminated(Closure was recomme... 展开 >>nded by CTEP due to slow accrual.) 收起 <<	-	United States, Michigan ... 展开 >> Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201 Wayne State University Detroit, Michigan, United States, 48202 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 收起 <<
NCT00454805	-		Completed	-	-
NCT00527124	-		Terminated(Closure was recomme... 展开 >>nded by CTEP due to slow accrual.) 收起 <<	-	-
NCT02446600	BRCA Rearrangement ... 展开 >> Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Fallopian Tube Undifferentiated Carcinoma Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Tumor Ovarian Seromucinous Carcinoma Ovarian Serous Tumor Ovarian Transitional Cell Carcinoma Ovarian Undifferentiated Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Ovarian Endometrioid Adenocarcinoma Recurrent Primary Peritoneal Carcinoma 收起 <<	Phase 3	Active, not recruiting	-	-
NCT00410904	Recurrent Non-small Cell Lung ... 展开 >>Cancer 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 收起 <<
NCT00427973	Adult Primary Hepatocellular C... 展开 >>arcinoma Advanced Adult Primary Liver Cancer Localized Unresectable Adult Primary Liver Cancer Recurrent Adult Primary Liver Cancer 收起 <<	Phase 2	Terminated(The study was stopp... 展开 >>ed prior to 2nd stage.) 收起 <<	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 收起 <<
NCT00427973	-		Terminated(The study was stopp... 展开 >>ed prior to 2nd stage.) 收起 <<	-	-
NCT00501605	Advanced Solid Tumor ... 展开 >> Liver Metastases 收起 <<	Phase 1	Completed	-	Germany ... 展开 >> Research Site Freiburg, Germany 收起 <<
NCT00662506	Adult Giant Cell Glioblastoma ... 展开 >> Adult Glioblastoma Adult Gliosarcoma 收起 <<	Phase 1 Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT00503477	Advanced Solid Tumor	Phase 1	Completed	-	Japan ... 展开 >> Research Site Shizuoka, Japan Research Site Tokyo, Japan 收起 <<
NCT00410904	-		Completed	-	-
NCT00502060	Advanced Tumor	Phase 1	Completed	-	Netherlands ... 展开 >> Research Site Amsterdam, Netherlands Research Site Nijmegen, Netherlands Research Site Utrecht, Netherlands 收起 <<
NCT01062425	-		Active, not recruiting	-	-
NCT00795340	Lung Cancer	Phase 3	Completed	-	Brazil ... 展开 >> Instituto Nacional de Cancer (INCA) Rio de Janeiro, Brazil, CEP20231-050 Instituto de Cancer Arnaldo Vieira de Carvalho Sao Paulo, Brazil, 01224-010 Canada, Alberta Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia BCCA - Abbotsford Centre Abbotsford, British Columbia, Canada, V2S 0C2 BCCA - Fraser Valley Cancer Centre Surrey, British Columbia, Canada, V3V 1Z2 BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Cancer Centre of Southeastern Ontario at Kingston Kingston, Ontario, Canada, K7L 5P9 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 Ottawa Health Research Institute - General Division Ottawa, Ontario, Canada, K1H 8L6 Algoma District Cancer Program Sault Ste. Marie, Ontario, Canada, P6B 0A8 Niagara Health System St. Catharines, Ontario, Canada, L2R 7C6 Mount Sinai Hospital Toronto, Ontario, Canada, M5G 1X5 Univ. Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Windsor Regional Cancer Centre Windsor, Ontario, Canada, N8W 2X3 Canada, Quebec McGill University - Dept. Oncology Montreal, Quebec, Canada, H2W 1S6 Canada, Saskatchewan Allan Blair Cancer Centre Regina, Saskatchewan, Canada, S4T 7T1 Canada University Institute of Cardiology and Quebec, Canada, G1V 4G5 收起 <<
NCT01062425	Adult Glioblastoma ... 展开 >> Adult Gliosarcoma 收起 <<	Phase 2	Active, not recruiting	-	-
NCT00539331	Carcinoma, Non-Small-Cell Lung	Phase 1	Terminated	-	Japan ... 展开 >> Research Site Osaka, Japan Research Site Tokyo, Japan 收起 <<
NCT00795340	-		Completed	-	-
NCT03314740	Ovarian Neoplasms	Phase 2	Recruiting	November 30, 2019	Italy ... 展开 >> Spedali Civili di Brescia Recruiting Brescia, BS, Italy, 25123 Contact: Germana Tognon, MD +39 03/03995341 germanatognon@alice.it Ospedale San Gerardo - ASST Monza Recruiting Monza, MB, Italy, 20900 Contact: Andrea Lissoni, MD +39 039/2339677 andreaalberto.lissoni@unimib.it Istituto Oncologico Veneto (IOV) Recruiting Padova, PD, Italy, 35128 Contact: Ornella Nicoletto, MD +39 049/8215913 ornella.nicoletto@iov.veneto.it Arcispedale Santa Maria Nuova Recruiting Reggio Emilia, RE, Italy, 42123 Contact: Alessandra Bologna, MD +39 05/22295181 alessandra.bologna@ausl.re.it Policlinico Umberto I - Università La Sapienza Recruiting Rome, RM, Italy, 00161 Contact: Pierluigi Benedetti Panici +39 06/49976300 pierluigi.benedettipanici@uniroma1.it Istituto Eurpeo di Oncologia (IEO) Recruiting Milano, Italy, 20141 Contact: Nicoletta Colombo, MD 0039 02 57489562 nicoletta.colombo@ieo.it 收起 <<
NCT01064648	Epithelioid Mesothelioma ... 展开 >> Pleural Malignant Mesothelioma Recurrent Malignant Mesothelioma Sarcomatoid Mesothelioma 收起 <<	Phase 1 Phase 2	Active, not recruiting	-	-
NCT00245063	-		Completed	-	-
NCT00939848	Biliary Tract Neoplasms	Phase 2 Phase 3	Completed	-	United Kingdom ... 展开 >> University College London Hospitals NHS Foundation Trust London, United Kingdom, NW1 2PQ The Christie NHS Foundation Trust Manchester, United Kingdom, M20 4BX 收起 <<
NCT00588900	-		Terminated	-	-
NCT00960349	Gastric Cancer	Phase 1	Completed	-	Japan ... 展开 >> Research Site Nagoya, Aichi, Japan Research Site Osakasayama, Osaka, Japan Research Site Sunto-gun, Shizuoka, Japan Research Site Chuo, Tokyo, Japan 收起 <<
NCT00588900	Colorectal Cancer	Phase 2	Terminated	-	United States, Illinois ... 展开 >> Evanston Hospital Evanston, Illinois, United States, 60201-1781 United States, Indiana Elkhart Clinic, LLC Elkhart, Indiana, United States, 46514-2098 Elkhart General Hospital Elkhart, Indiana, United States, 46515 Fort Wayne Medical Oncology and Hematology Fort Wayne, Indiana, United States, 46845 Howard Community Hospital Kokomo, Indiana, United States, 46904 Center for Cancer Therapy at LaPorte Hospital and Health Services La Porte, Indiana, United States, 46350 CCOP - Northern Indiana CR Consortium South Bend, Indiana, United States, 46601 Memorial Hospital of South Bend South Bend, Indiana, United States, 46601 Michiana Hematology-Oncology, PC - South Bend South Bend, Indiana, United States, 46601 Saint Joseph Regional Medical Center South Bend, Indiana, United States, 46617 South Bend Clinic South Bend, Indiana, United States, 46617 United States, Iowa Hematology Oncology Associates of the Quad Cities Bettendorf, Iowa, United States, 52722 Holden Comprehensive Cancer Center at University of Iowa Iowa City, Iowa, United States, 52242-1002 United States, Michigan Lakeside Cancer Specialists, PLLC Saint Joseph, Michigan, United States, 49085 Lakeland Regional Cancer Care Center - St. Joseph St. Joseph, Michigan, United States, 49085 United States, Missouri Ellis Fischel Cancer Center at University of Missouri - Columbia Columbia, Missouri, United States, 65203 United States, Nebraska Cancer Resource Center - Lincoln Lincoln, Nebraska, United States, 68510 CCOP - Missouri Valley Cancer Consortium Omaha, Nebraska, United States, 68106 Immanuel Medical Center Omaha, Nebraska, United States, 68122 Alegant Health Cancer Center at Bergan Mercy Medical Center Omaha, Nebraska, United States, 68124 Creighton University Medical Center Omaha, Nebraska, United States, 68131-2197 United States, New Hampshire New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care Concord, New Hampshire, United States, 03301 New Hampshire Oncology - Hematology, PA - Hooksett Hooksett, New Hampshire, United States, 03106 Lakes Region General Hospital Laconia, New Hampshire, United States, 03246 United States, New York CCOP - Hematology-Oncology Associates of Central New York East Syracuse, New York, United States, 13057 United States, North Carolina Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States, 27599-7295 Wayne Memorial Hospital, Incorporated Goldsboro, North Carolina, United States, 27534 Kinston Medical Specialists Kinston, North Carolina, United States, 28501 Rex Cancer Center at Rex Hospital Raleigh, North Carolina, United States, 27607 Iredell Memorial Hospital Statesville, North Carolina, United States, 28677 Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina, United States, 27157-1096 收起 <<
NCT00227760	Recurrent Renal Cell Carcinoma... 展开 >> Stage IV Renal Cell Cancer 收起 <<	Phase 2	Completed	-	Canada, Alberta ... 展开 >> Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 The Ottawa Hospital Cancer Centre (Ottawa Health Research Institute) Civic Campus Ottawa, Ontario, Canada, K1Y 4E9 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00227760	-		Completed	-	-
NCT00436956	-		Completed	-	-
NCT00243347	Carcinoma Non... 展开 >>-Small-Cell Lung Carcinoma Head and Neck Neoplasms 收起 <<	Phase 1	Completed	-	United States, Texas ... 展开 >> Research Site Houston, Texas, United States Spain Research Site Barcelona, Spain 收起 <<
NCT00305656	Adult Giant Cell Glioblastoma ... 展开 >> Adult Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Tumor 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 收起 <<
NCT00436956	Prostate Cancer	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT03117933	Ovarian Cancer	Phase 2	Recruiting	November 30, 2021	United Kingdom ... 展开 >> Belfast City Hospital Recruiting Belfast, County Antrim, United Kingdom, BT9 7AM Principal Investigator: Sarah McKenna Mount Vernon Cancer Centre Recruiting Northwood, Middlesex, United Kingdom Principal Investigator: Marcia Hall City Hospital Nottingham Recruiting Nottingham, Nottinghamshire, United Kingdom, NG5 1PB Principal Investigator: Anjana Anand Royal Surrey County Hospital Recruiting Guildford, Surrey, United Kingdom, GU2 7XX Principal Investigator: Agnieszka Michael Royal United Hospital Recruiting Bath, United Kingdom Principal Investigator: Rebecca Bowen Velindre Recruiting Cardiff, United Kingdom Principal Investigator: Emma Hudson Ninewells Hospital Not yet recruiting Dundee, United Kingdom Principal Investigator: Michelle Ferguson Beatson West of Scotland Cancer Centre Recruiting Glasgow, United Kingdom Principal Investigator: Ros Glasspool Clatterbridge Cancer Centre Recruiting Liverpool, United Kingdom Principal Investigator: Rosemary Lord St Bartholomew's Recruiting London, United Kingdom, EC1A 7BE Principal Investigator: Rowan Miller Hammersmith Hospital Recruiting London, United Kingdom, W12 0HS Principal Investigator: Iain McNeish Royal Marsden Chelsea & Sutton Recruiting London, United Kingdom Principal Investigator: Susana Banerjee University College London Recruiting London, United Kingdom Principal Investigator: Rebecca Kristeleit The Christie Recruiting Manchester, United Kingdom Principal Investigator: Andrew Clamp Churchill Hospital Recruiting Oxford, United Kingdom, OX3 7LE Principal Investigator: Shibani Nicum 收起 <<
NCT00243074	-		Completed	-	-
NCT00245063	Recurrent Non-small Cell Lung ... 展开 >>Cancer 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> City of Hope Duarte, California, United States, 91010 收起 <<
NCT00458978	Recurrent Hypopharyngeal Squam... 展开 >>ous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Laryngeal Verrucous Carcinoma Recurrent Lip and Oral Cavity Squamous Cell Carcinoma Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma Recurrent Oral Cavity Verrucous Carcinoma Recurrent Oropharyngeal Squamous Cell Carcinoma Recurrent Salivary Gland Carcinoma Salivary Gland Squamous Cell Carcinoma Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary Stage IV Hypopharyngeal Squamous Cell Carcinoma Stage IV Laryngeal Squamous Cell Carcinoma Stage IV Laryngeal Verrucous Carcinoma Stage IV Lip and Oral Cavity Squamous Cell Carcinoma Stage IV Major Salivary Gland Carcinoma Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma Stage IV Oral Cavity Verrucous Carcinoma Stage IV Oropharyngeal Squamous Cell Carcinoma Tongue Carcinoma Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 收起 <<
NCT00243347	-		Completed	-	-
NCT00243074	Advanced Malignant Mesotheliom... 展开 >>a Epithelial Mesothelioma Recurrent Malignant Mesothelioma Sarcomatous Mesothelioma 收起 <<	Phase 2	Completed	-	United States, Texas ... 展开 >> Southwest Oncology Group San Antonio, Texas, United States, 78245 收起 <<
NCT00321724	B-cell Chronic Lymphocytic Leu... 展开 >>kemia Refractory Chronic Lymphocytic Leukemia 收起 <<	Phase 2	Completed	-	United States, Minnesota ... 展开 >> North Central Cancer Treatment Group Rochester, Minnesota, United States, 55905 收起 <<
NCT00303862	Clear Cell Renal Cell Carcinom... 展开 >>a Recurrent Renal Cell Cancer Stage IV Renal Cell Cancer 收起 <<	Phase 2	Terminated	-	United States, Illinois ... 展开 >> University of Chicago Chicago, Illinois, United States, 60637 收起 <<
NCT00777153	-		Completed	-	-
NCT00503412	Advanced Solid Metastatic Tumo... 展开 >>r 收起 <<	Phase 1	Completed	-	United Kingdom ... 展开 >> Research Site Sutton, United Kingdom 收起 <<
NCT01310855	Glioblastoma	Phase 2	Terminated(closed to recruitme... 展开 >>nt early due to AstraZeneca not developing cediranib further) 收起 <<	-	United Kingdom ... 展开 >> University College Hospital London, England, United Kingdom, NW1 2BU Queen Elizabeth Hospital Birmingham, United Kingdom Bristol Haematology and Oncology Centre Bristol, United Kingdom Addenbrooke's Hospital Cambridge, United Kingdom Royal Surrey County Hospital Guildford, United Kingdom Castle Hill Hospital Hull, United Kingdom Charing Cross Hospital London, United Kingdom The Christie NHS Foundation Trust Manchester, United Kingdom Southampton General Hospital Southampton, United Kingdom Royal Marsden Hospital Sutton, United Kingdom 收起 <<
NCT00303862	-		Terminated	-	-
NCT00244881	Male Breast Cancer ... 展开 >> Recurrent Breast Cancer Stage IV Breast Cancer 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00244881	-		Completed	-	-
NCT00326664	Childhood Atypical Teratoid/Rh... 展开 >>abdoid Tumor Childhood Central Nervous System Germ Cell Tumor Childhood Cerebral Anaplastic Astrocytoma Childhood Cerebral Astrocytoma Childhood Grade I Meningioma Childhood Grade II Meningioma Childhood Grade III Meningioma Childhood Infratentorial Ependymoma Childhood Oligodendroglioma Childhood Spinal Cord Neoplasm Childhood Supratentorial Ependymoma Recurrent Childhood Brain Neoplasm Recurrent Childhood Brain Stem Glioma Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood Cerebral Astrocytoma Recurrent Childhood Ependymoma Recurrent Childhood Medulloblastoma Recurrent Childhood Pineoblastoma Recurrent Childhood Subependymal Giant Cell Astrocytoma Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Recurrent Childhood Visual Pathway Glioma 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> UCSF Medical Center-Mount Zion San Francisco, California, United States, 94115 United States, District of Columbia Children's National Medical Center Washington, District of Columbia, United States, 20010 United States, Illinois Lurie Children's Hospital-Chicago Chicago, Illinois, United States, 60611 United States, Massachusetts Dana-Farber/Harvard Cancer Center Boston, Massachusetts, United States, 02115 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania, United States, 15224 United States, Tennessee Pediatric Brain Tumor Consortium Memphis, Tennessee, United States, 38105 St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 United States, Texas Texas Children's Hospital Houston, Texas, United States, 77030 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 收起 <<
NCT00777153	Recurrent Glioblastoma	Phase 3	Completed	-	-
NCT00326872	Neurofibromatosis Type 1 ... 展开 >> Plexiform Neurofibroma Spinal Cord Neurofibroma 收起 <<	Phase 2	Terminated(Closed due to slow ... 展开 >>accrual prior to interim analysis.) 收起 <<	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States, 35233 United States, District of Columbia Howard University Hospital Washington, D.C., District of Columbia, United States, 20060 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 United States, Massachusetts Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 收起 <<
NCT00326872	-		Terminated(Closed due to slow ... 展开 >>accrual prior to interim analysis.) 收起 <<	-	-
NCT00385203	Gastrointestinal Stromal Tumor... 展开 >>s Soft Tissue Sarcomas 收起 <<	Phase 2	Completed	-	United Kingdom ... 展开 >> Research Site Manchester, United Kingdom Research Site Sutton, United Kingdom 收起 <<
NCT00385203	-		Completed	-	-
NCT01310855	-		Terminated(closed to recruitme... 展开 >>nt early due to AstraZeneca not developing cediranib further) 收起 <<	-	-
NCT01229111	Adult Primary Cholangiocellula... 展开 >>r Carcinoma Advanced Adult Primary Liver Cancer Cholangiocarcinoma of the Extrahepatic Bile Duct Cholangiocarcinoma of the Gallbladder Localized Unresectable Adult Primary Liver Cancer Periampullary Adenocarcinoma Recurrent Adult Primary Liver Cancer Recurrent Extrahepatic Bile Duct Cancer Recurrent Gallbladder Cancer Unresectable Extrahepatic Bile Duct Cancer Unresectable Gallbladder Cancer 收起 <<	Phase 2	Terminated(Lack of Drug Supply... 展开 >>) 收起 <<	-	United States, Ohio ... 展开 >> Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 Ireland Cancer Center Landerbrook Health Center Mayfield Heights, Ohio, United States, 44124 Lake University Ireland Cancer Center Mentor, Ohio, United States, 44060 UHHS-Chagrin Highlands Medical Center Orange Village, Ohio, United States, 44122 UH-Seidman Cancer Center at Saint John Medical Center Westlake, Ohio, United States, 44145 收起 <<
NCT01229111	-		Terminated(Lack of Drug Supply... 展开 >>) 收起 <<	-	-
NCT00942877	Sarcoma, Alveolar Soft Part	Phase 2	Active, not recruiting	September 30, 2020	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT02484404	Lung Cancer B... 展开 >>reast Cancer Ovarian Cancer Colorectal Cancer Prostate Cancer Triple Negative Breast Cancer 收起 <<	Phase 1 Phase 2	Recruiting	December 31, 2019	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 收起 <<
NCT00399035	Metastatic Colorectal Cancer	Phase 3	Completed	-	-
NCT00399035	-		Completed	-	-
NCT00243061	Acral Lentiginous Malignant Me... 展开 >>lanoma Ciliary Body and Choroid Melanoma, Medium/Large Size Ciliary Body and Choroid Melanoma, Small Size Extraocular Extension Melanoma Intraocular Melanoma Iris Melanoma Lentigo Maligna Malignant Melanoma Recurrent Melanoma Stage, Intraocular Melanoma Stage IV Melanoma Superficial Spreading Malignant Melanoma 收起 <<	Phase 2	Completed	-	Canada, Ontario ... 展开 >> Princess Margaret Hospital Phase 2 Consortium Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00502164	Advanced Prostate Adenocarcino... 展开 >>ma 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> Research Site San Francisco, California, United States United States, Illinois Research Site Chicago, Illinois, United States United States, Tennessee Research Site Nashville, Tennessee, United States 收起 <<
NCT00275028	-		Completed	-	-
NCT02974621	Recurrent Glioblastoma	Phase 2	Suspended(Other - Awaiting CTE... 展开 >>P Approval of Amendment v.10/15/18) 收起 <<	October 31, 2019	-
NCT00243061	-		Completed	-	-
NCT01364051	Solid Neoplasm ... 展开 >> Stage IV Cutaneous Melanoma AJCC v6 and v7 收起 <<	Phase 1	Active, not recruiting	-	United States, Florida ... 展开 >> Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT00621361	Lung Cancer	Phase 1	Completed	-	United States, California ... 展开 >> Research Site Sacramento, California, United States United States, Colorado Research Site Denver, Colorado, United States United States, Kansas Research Site Kansas City, Kansas, United States United States, Texas Research Site Houston, Texas, United States 收起 <<
NCT00748891	Cancer	Phase 1	Completed	-	United Kingdom ... 展开 >> Research Site London, United Kingdom 收起 <<
NCT00475150	Adult Acute Myeloid Leukemia W... 展开 >>ith 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) de Novo Myelodysplastic Syndromes Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndromes Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Completed	-	United States, District of Col... 展开 >>umbia Howard University Hospital Washington, District of Columbia, United States, 20060 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Maryland Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 收起 <<
NCT00275028	Fallopian Tube Cancer ... 展开 >> Primary Peritoneal Serous Adenocarcinoma Recurrent Ovarian Epithelial Cancer Stage I Ovarian Epithelial Cancer Stage II Ovarian Epithelial Cancer 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00475150	-		Completed	-	-
NCT02498613	Estrogen Receptor Negative ... 展开 >> HER2/Neu Negative Metastatic Pancreatic Adenocarcinoma Pancreatic Ductal Adenocarcinoma Progesterone Receptor Negative Stage III Breast Cancer AJCC v7 Stage III Non-Small Cell Lung Cancer AJCC v7 Stage III Pancreatic Cancer AJCC v6 and v7 Stage III Small Cell Lung Carcinoma AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7 Stage IIIA Small Cell Lung Carcinoma AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIB Lung Non-Small Cell Cancer AJCC v7 Stage IIIB Small Cell Lung Carcinoma AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7 Stage IV Non-Small Cell Lung Cancer AJCC v7 Stage IV Pancreatic Cancer AJCC v6 and v7 Stage IV Small Cell Lung Carcinoma AJCC v7 Triple-Negative Breast Carcinoma Unresectable Pancreatic Carcinoma 收起 <<	Phase 2	Recruiting	June 30, 2019	United States, California ... 展开 >> UC San Diego Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Site Public Contact 858-822-5354 cancercto@ucsd.edu Principal Investigator: Shumei Kato University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact 916-734-3089 Principal Investigator: Primo N. Lara University of California San Diego Recruiting San Diego, California, United States, 92103 Contact: Site Public Contact 858-822-5354 cancercto@ucsd.edu Principal Investigator: Shumei Kato UCSF Medical Center-Mount Zion Recruiting San Francisco, California, United States, 94115 Contact: Site Public Contact 877-827-3222 Principal Investigator: Pamela N. Munster United States, Connecticut Smilow Cancer Center/Yale-New Haven Hospital Recruiting New Haven, Connecticut, United States, 06510 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Joseph W. Kim Yale University Recruiting New Haven, Connecticut, United States, 06520 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Joseph W. Kim United States, Florida Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Site Public Contact 800-456-7121 canceranswers@moffitt.org Principal Investigator: Hatem H. Soliman United States, Michigan Wayne State University/Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Site Public Contact 313-576-9790 ctoadmin@karmanos.org Principal Investigator: Ulka N. Vaishampayan Weisberg Cancer Treatment Center Recruiting Farmington Hills, Michigan, United States, 48334 Contact: Site Public Contact 313-576-9790 ctoadmin@karmanos.org Principal Investigator: Ulka N. Vaishampayan United States, Tennessee Vanderbilt University/Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Site Public Contact 800-811-8480 Principal Investigator: Dana B. Cardin United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact 877-312-3961 Principal Investigator: Siqing Fu United States, Virginia Virginia Commonwealth University/Massey Cancer Center Recruiting Richmond, Virginia, United States, 23298 Contact: Site Public Contact mwellons@vcu.edu Principal Investigator: Sosipatros A. Boikos Canada, British Columbia BCCA-Vancouver Cancer Centre Recruiting Vancouver, British Columbia, Canada, V5Z 4E6 Contact: Site Public Contact 888-939-3333 Principal Investigator: Daniel J. Renouf Canada, Ontario University Health Network-Princess Margaret Hospital Suspended Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00475956	Neoplasms	Phase 1	Completed	-	Germany ... 展开 >> Research Site Freiburg, Baden-Wurttemberg, Germany Research Site Essen, Ruhr, Germany Research Site Herne, Ruhr, Germany 收起 <<
NCT00264004	Tumors	Phase 2	Completed	-	Germany ... 展开 >> Research Site Freiburg, Germany Research Site Hamburg, Germany Netherlands Research Site Amsterdam, Netherlands Research Site Nijmegen, Netherlands Research Site Utrecht, Netherlands United Kingdom Research Site Surrey, United Kingdom 收起 <<
NCT01260688	-		Completed	-	-
NCT00238394	Adult Primary Hepatocellular C... 展开 >>arcinoma Advanced Adult Primary Liver Cancer Localized Unresectable Adult Primary Liver Cancer 收起 <<	Phase 2	Completed	-	United States, Minnesota ... 展开 >> North Central Cancer Treatment Group Rochester, Minnesota, United States, 55905 收起 <<
NCT01260688	Hormone Refractory Prostate Ca... 展开 >>ncer Recurrent Prostate Cancer 收起 <<	Phase 2	Completed	-	United States, Illinois ... 展开 >> Illinois CancerCare-Peoria Peoria, Illinois, United States, 61615 Central Illinois Hematology Oncology Center Springfield, Illinois, United States, 60702 United States, Indiana Fort Wayne Medical Oncology and Hematology Inc - State Boulevard Fort Wayne, Indiana, United States, 46845 United States, Maryland Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 Canada, British Columbia BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT01065662	Endometrial Cancer ... 展开 >> Ovarian Cancer Cervical Cancer Fallopian Tube Cancer Peritoneal Cancer 收起 <<	Phase 1	Active, not recruiting	December 2018	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00278343	Recurrent Fallopian Tube Cance... 展开 >>r Recurrent Ovarian Epithelial Cancer Recurrent Primary Peritoneal Cavity Cancer 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> City of Hope Duarte, California, United States, 91010 University of Southern California/Norris Cancer Center Los Angeles, California, United States, 90033 City of Hope Medical Group Inc Pasadena, California, United States, 91105 University of California at Davis Cancer Center Sacramento, California, United States, 95817 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 Decatur Memorial Hospital Decatur, Illinois, United States, 62526 Evanston Hospital CCOP Evanston, Illinois, United States, 60201 Ingalls Memorial Hospital Harvey, Illinois, United States, 60426 Joliet Oncology-Hematology Associates Limited Joliet, Illinois, United States, 60435 Loyola University Medical Center Maywood, Illinois, United States, 60153 Peoria Gynecologic Oncology Peoria, Illinois, United States, 61603 Oncology/Hematology Associates Peoria, Illinois, United States, 61615-7828 Central Illinois Hematology Oncology Center Springfield, Illinois, United States, 60702 United States, Indiana Fort Wayne Medical Oncology and Hematology Inc-Parkview Fort Wayne, Indiana, United States, 46845 Northern Indiana Cancer Research Consortium South Bend, Indiana, United States, 46628 United States, Maryland University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109-0944 Oncology Care Associates PLLC Saint Joseph, Michigan, United States, 49085 United States, Missouri Saint John's Mercy Medical Center Saint Louis, Missouri, United States, 63141 United States, Pennsylvania University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 United States, Wisconsin Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Cancer Centre of Southeastern Ontario at Kingston General Hospital Kingston, Ontario, Canada, K7L 5P9 London Health Sciences Centre-South Street London, Ontario, Canada, N6A 4G5 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 The Ottawa Hospital Cancer Centre (Ottawa Health Research Institute) Civic Campus Ottawa, Ontario, Canada, K1Y 4E9 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec CHUM - Hopital Notre-Dame Montreal, Quebec, Canada, H2L 4M1 收起 <<
NCT00278343	-		Completed	-	-
NCT00494221	Metastatic Colorectal Cancer	Phase 1 Phase 2	Completed	-	Japan ... 展开 >> Research Site Osaka, Japan Research Site Saitama, Japan 收起 <<
NCT00309946	-		Completed	-	-
NCT00264004	-		Completed	-	-
NCT00309946	Advanced Malignant Mesotheliom... 展开 >>a Epithelial Mesothelioma Localized Malignant Mesothelioma Recurrent Malignant Mesothelioma Sarcomatous Mesothelioma 收起 <<	Phase 2	Completed	-	United States, Illinois ... 展开 >> University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637-1470 收起 <<
NCT00494221	-		Completed	-	-
NCT00937482	Male Breast Cancer ... 展开 >> Stage IV Breast Cancer Stage IV Melanoma Stage IV Non-small Cell Lung Cancer Stage IV Renal Cell Cancer Stage IVA Colon Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Rectal Cancer Tumors Metastatic to Brain 收起 <<	Phase 1	Terminated(Administratively co... 展开 >>mplete.) 收起 <<	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 收起 <<
NCT00423332	Renal Cell Carcinoma	Phase 2	Completed	-	Netherlands ... 展开 >> Research Site Groningen, Netherlands Research Site Leiden, Netherlands Research Site Nijmegen, Netherlands United Kingdom Research Site Birmingham, United Kingdom Research Site London, United Kingdom Research Site Manchester, United Kingdom Research Site Northwood, United Kingdom Research Site Oxford, United Kingdom 收起 <<
NCT00458731	Adult Grade III Lymphomatoid G... 展开 >>ranulomatosis Adult Nasal Type Extranodal NK/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Childhood Burkitt Lymphoma Childhood Diffuse Large Cell Lymphoma Childhood Grade III Lymphomatoid Granulomatosis Childhood Immunoblastic Large Cell Lymphoma Childhood Nasal Type Extranodal NK/T-cell Lymphoma Cutaneous B-cell Non-Hodgkin Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Hepatosplenic T-cell Lymphoma Intraocular Lymphoma Nodal Marginal Zone B-cell Lymphoma Noncutaneous Extranodal Lymphoma Peripheral T-cell Lymphoma Progressive Hairy Cell Leukemia, Initial Treatment Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-cell Leukemia/Lymphoma Recurrent Childhood Anaplastic Large Cell Lymphoma Recurrent Childhood Large Cell Lymphoma Recurrent Childhood Lymphoblastic Lymphoma Recurrent Childhood Small Noncleaved Cell Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent/Refractory Childhood Hodgkin Lymphoma Refractory Hairy Cell Leukemia Small Intestine Lymphoma Splenic Marginal Zone Lymphoma Stage IV Adult Burkitt Lymphoma Stage IV Adult Diffuse Large Cell Lymphoma Stage IV Adult Diffuse Mixed Cell Lymphoma Stage IV Adult Diffuse Small Cleaved Cell Lymphoma Stage IV Adult Hodgkin Lymphoma Stage IV Adult Immunoblastic Large Cell Lymphoma Stage IV Adult Lymphoblastic Lymphoma Stage IV Adult T-cell Leukemia/Lymphoma Stage IV Childhood Anaplastic Large Cell Lymphoma Stage IV Childhood Hodgkin Lymphoma Stage IV Childhood Large Cell Lymphoma Stage IV Childhood Lymphoblastic Lymphoma Stage IV Childhood Small Noncleaved Cell Lymphoma Stage IV Grade 1 Follicular Lymphoma Stage IV Grade 2 Follicular Lymphoma Stage IV Grade 3 Follicular Lymphoma Stage IV Mantle Cell Lymphoma Stage IVA Mycosis Fungoides/Sezary Syndrome Stage IVB Mycosis Fungoides/Sezary Syndrome T-cell Large Granular Lymphocyte Leukemia Testicular Lymphoma Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific Waldenström Macroglobulinemia 收起 <<	Phase 1	Completed	-	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01131234	Adult Anaplastic Astrocytoma ... 展开 >> Adult Anaplastic Ependymoma Adult Anaplastic Oligodendroglioma Adult Brain Stem Glioma Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Adult Mixed Glioma Adult Solid Neoplasm Male Breast Carcinoma Recurrent Adult Brain Neoplasm Recurrent Breast Carcinoma Recurrent Colon Carcinoma Recurrent Melanoma Recurrent Non-Small Cell Lung Carcinoma Recurrent Ovarian Carcinoma Recurrent Ovarian Germ Cell Tumor Recurrent Pancreatic Carcinoma Recurrent Rectal Carcinoma Recurrent Renal Cell Carcinoma Stage III Pancreatic Cancer Stage III Renal Cell Cancer Stage IIIA Colon Cancer Stage IIIA Non-Small Cell Lung Cancer Stage IIIA Ovarian Cancer Stage IIIA Ovarian Germ Cell Tumor Stage IIIA Rectal Cancer Stage IIIA Skin Melanoma Stage IIIB Breast Cancer Stage IIIB Colon Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IIIB Ovarian Cancer Stage IIIB Ovarian Germ Cell Tumor Stage IIIB Rectal Cancer Stage IIIB Skin Melanoma Stage IIIC Breast Cancer Stage IIIC Colon Cancer Stage IIIC Ovarian Cancer Stage IIIC Ovarian Germ Cell Tumor Stage IIIC Rectal Cancer Stage IIIC Skin Melanoma Stage IV Breast Cancer Stage IV Non-Small Cell Lung Cancer Stage IV Ovarian Cancer Stage IV Ovarian Germ Cell Tumor Stage IV Pancreatic Cancer Stage IV Renal Cell Cancer Stage IV Skin Melanoma Stage IVA Colon Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Rectal Cancer 收起 <<	Phase 1	Completed	-	Canada, Ontario ... 展开 >> Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT02345265	Deleterious BRCA1 Gene Mutatio... 展开 >>n Deleterious BRCA2 Gene Mutation Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Serous Adenocarcinoma High Grade Ovarian Serous Adenocarcinoma Ovarian Endometrioid Tumor Primary Peritoneal Serous Adenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma 收起 <<	Phase 2	Active, not recruiting	February 1, 2019	United States, Arizona ... 展开 >> Mayo Clinic Hospital Phoenix, Arizona, United States, 85054 Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, California City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 Los Angeles County-USC Medical Center Los Angeles, California, United States, 90033 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 Keck Medical Center of USC Pasadena Pasadena, California, United States, 91105 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 National Institutes of Health Clinical Center Bethesda, Maryland, United States, 20892 NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 United States, Massachusetts Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New Jersey Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital New Brunswick, New Jersey, United States, 08903 Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 收起 <<
NCT00306891	Cancer	Phase 2	Completed	-	United Kingdom ... 展开 >> Research Site Glasgow, United Kingdom Research Site Headington, United Kingdom Research Site London, United Kingdom Research Site Manchester, United Kingdom 收起 <<
NCT01116648	Deleterious BRCA1 Gene Mutatio... 展开 >>n Deleterious BRCA2 Gene Mutation Estrogen Receptor Negative HER2/Neu Negative Ovarian Endometrioid Adenocarcinoma Ovarian Serous Adenocarcinoma Ovarian Serous Surface Papillary Adenocarcinoma Progesterone Receptor Negative Recurrent Breast Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Triple-Negative Breast Carcinoma 收起 <<	Phase 1 Phase 2	Active, not recruiting	-	United States, California ... 展开 >> Cedars Sinai Medical Center Los Angeles, California, United States, 90048 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States, 60201 United States, Indiana Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard Fort Wayne, Indiana, United States, 46804 Fort Wayne Medical Oncology and Hematology Inc-Parkview Fort Wayne, Indiana, United States, 46845 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 National Institutes of Health Clinical Center Bethesda, Maryland, United States, 20892 National Cancer Institute Rockville, Maryland, United States, 20850 United States, Massachusetts Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Massachusetts General Hospital Charlestown, Massachusetts, United States, 02129 Newton-Wellesley Hospital Newton, Massachusetts, United States, 02462 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 收起 <<
NCT01160926	Rectal Cancer	Phase 1	Terminated(2 DLTs had been rep... 展开 >>orted from first 4 patients on lowest possible dose cohort.) 收起 <<	September 2016	United Kingdom ... 展开 >> The Christie NHS Foundation Trust Manchester, United Kingdom, M20 4BX 收起 <<
NCT00306891	-		Completed	-	-
NCT03570437	Carcinosarcoma ... 展开 >> Endometrial Neoplasms 收起 <<	Phase 2	Recruiting	September 30, 2021	United Kingdom ... 展开 >> Mount Vernon Cancer Centre Recruiting Northwood, Middlesex, United Kingdom, HA6 2RN Contact: Marcia Hall 020 3826 2442 University College London Hospitals NHS Foundation Trust Recruiting London, United Kingdom, NW1 2BU Contact: Rebecca Kristeleit r.kristeleit@ucl.ac.uk Principal Investigator: Rebecca Kristeleit The Christie NHS Foundation Trust Recruiting Manchester, United Kingdom, M20 4BX Contact: Andrew Clamp 0161 446 3391 Andrew.Clamp@christie.nhs.uk Contact: Gordon Jayson 0161 446 3391 Gordon.jayson@christie.nhs.uk 收起 <<
NCT01208051	Recurrent Thyroid Gland Carcin... 展开 >>oma Stage I Thyroid Gland Follicular Carcinoma AJCC v7 Stage I Thyroid Gland Papillary Carcinoma AJCC v7 Stage II Thyroid Gland Follicular Carcinoma AJCC v7 Stage II Thyroid Gland Papillary Carcinoma AJCC v7 Stage III Thyroid Gland Follicular Carcinoma AJCC v7 Stage III Thyroid Gland Papillary Carcinoma AJCC v7 Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7 收起 <<	Phase 1 Phase 2	Active, not recruiting	September 30, 2018	-
NCT01132820	Endometrial Adenocarcinoma ... 展开 >> Endometrial Adenosquamous Carcinoma Endometrial Clear Cell Adenocarcinoma Endometrial Serous Adenocarcinoma Recurrent Uterine Corpus Carcinoma 收起 <<	Phase 2	Completed	-	-
NCT03660826	Endometrial Undifferentiated C... 展开 >>arcinoma Endometrioid Adenocarcinoma Recurrent Endometrial Serous Adenocarcinoma Recurrent Uterine Corpus Carcinoma Stage IV Uterine Corpus Cancer AJCC v7 Stage IVA Uterine Corpus Cancer AJCC v7 Stage IVB Uterine Corpus Cancer AJCC v7 收起 <<	Phase 2	Recruiting	September 4, 2020	-
NCT02681237	Ovarian Cancer	Not Applicable	Recruiting	October 2021	Canada, Ontario ... 展开 >> Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Amit Oza, M.D. 416-946-2818 Principal Investigator: Amit Oza, M.D. 收起 <<
NCT01132820	-		Completed	-	-
NCT00503204	Recurrent Glioblastoma ... 展开 >> Brain Tumor 收起 <<	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Research Site Boston, Massachusetts, United States United Kingdom Research Site Sutton, United Kingdom 收起 <<
NCT00979862	Adult Giant Cell Glioblastoma ... 展开 >> Adult Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Neoplasm 收起 <<	Phase 1	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35233 United States, Georgia Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Maryland Adult Brain Tumor Consortium Baltimore, Maryland, United States, 21231-1000 Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Massachusetts General Hospital Charlestown, Massachusetts, United States, 02129 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 United States, Ohio Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 收起 <<
NCT03278717	Ovarian Cancer	Phase 3	Not yet recruiting	December 2023	-
NCT02893917	Castration Levels of Testoster... 展开 >>one Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation Prostate Carcinoma Metastatic in the Bone Prostate Small Cell Carcinoma PSA Progression Stage IV Prostate Adenocarcinoma AJCC v7 收起 <<	Phase 2	Recruiting	-	United States, California ... 展开 >> UC San Diego Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Site Public Contact 858-822-5354 cancercto@ucsd.edu Principal Investigator: Rana R. McKay University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact 916-734-3089 Principal Investigator: Mamta Parikh University of California San Diego Recruiting San Diego, California, United States, 92103 Contact: Site Public Contact 858-822-5354 cancercto@ucsd.edu Principal Investigator: Rana R. McKay United States, Connecticut Smilow Cancer Center/Yale-New Haven Hospital Recruiting New Haven, Connecticut, United States, 06510 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Joseph W. Kim Yale University Recruiting New Haven, Connecticut, United States, 06520 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Joseph W. Kim United States, Florida Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Site Public Contact 800-456-7121 canceranswers@moffitt.org Principal Investigator: Jingsong Zhang United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Site Public Contact 877-726-5130 Principal Investigator: Mary-Ellen Taplin Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Site Public Contact 888-823-5923 ctsucontact@westat.com Principal Investigator: Mary-Ellen Taplin Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 617-667-9925 Principal Investigator: Mary-Ellen Taplin Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 877-442-3324 Principal Investigator: Mary-Ellen Taplin United States, Michigan Wayne State University/Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Site Public Contact 313-576-9790 ctoadmin@karmanos.org Principal Investigator: Ulka N. Vaishampayan Weisberg Cancer Treatment Center Recruiting Farmington Hills, Michigan, United States, 48334 Contact: Site Public Contact 313-576-9790 ctoadmin@karmanos.org Principal Investigator: Ulka N. Vaishampayan United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Site Public Contact 800-293-5066 Jamesline@osumc.edu Principal Investigator: J. P. Monk United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Site Public Contact 412-647-8073 Principal Investigator: Leonard J. Appleman United States, Tennessee Vanderbilt University/Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Site Public Contact 800-811-8480 Principal Investigator: Nancy B. Davis United States, Virginia Virginia Commonwealth University/Massey Cancer Center Recruiting Richmond, Virginia, United States, 23298 Contact: Site Public Contact mwellons@vcu.edu Principal Investigator: Asit K. Paul 收起 <<
NCT00621725	Advanced Cancer ... 展开 >> Hepatic Impairment 收起 <<	Phase 1	Completed	-	Denmark ... 展开 >> Research Site København Ø, Denmark Netherlands Research Site Nijmegen, Netherlands Research Site Rotterdam, Netherlands 收起 <<
NCT02889900	Recurrent Platinum Resistant O... 展开 >>varian Cancer 收起 <<	Phase 2	Recruiting	December 20, 2019	-
NCT02899728	Extensive Stage Lung Small Cel... 展开 >>l Carcinoma 收起 <<	Phase 2	Suspended(Other - Pending prot... 展开 >>ocol amendment) 收起 <<	April 7, 2020	United States, California ... 展开 >> Los Angeles County-USC Medical Center Los Angeles, California, United States, 90033 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 Keck Medical Center of USC Pasadena Pasadena, California, United States, 91105 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Emory University Hospital Midtown Atlanta, Georgia, United States, 30308 Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Kentucky University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States, 40536 United States, Massachusetts Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri Siteman Cancer Center at West County Hospital Creve Coeur, Missouri, United States, 63141 Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Siteman Cancer Center at Christian Hospital Saint Louis, Missouri, United States, 63136 Siteman Cancer Center at Saint Peters Hospital Saint Peters, Missouri, United States, 63376 United States, New York Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York, United States, 10016 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Pennsylvania Thomas Jefferson University Hospital Philadelphia, Pennsylvania, United States, 19107 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Virginia University of Virginia Cancer Center Charlottesville, Virginia, United States, 22908 Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT01337401	Alveolar Soft-part Sarcoma	Phase 2	Active, not recruiting	July 2019	Australia ... 展开 >> Princess Alexandra Hospital Brisbane, Australia Royal Prince Alfred Hospital Sydney, Australia Spain Hospital Santa Cruz i Sant Pau Barcelona, Spain Hospital Puerta de Hierro Madrid, Spain Hospital Miguel Servet Zaragoza, Spain United Kingdom Bristol Haematology and Oncology Centre Bristol, United Kingdom Royal Marsden Hospital London, United Kingdom University College London Hospital London, United Kingdom Christie Hospital Manchester, United Kingdom Royal Victoria Infirmary/Freeman Hospital Newcastle-Upon-Tyne, United Kingdom Nottingham University Hospitals Nottingham, United Kingdom 收起 <<
NCT01391962	Sarcoma, Alveolar Soft Part	Phase 2	Recruiting	December 15, 2019	United States, California ... 展开 >> Santa Monica Oncology Center Recruiting Santa Monica, California, United States, 90403 Contact: Shivaani Kummar, M.D. 301-435-5402 kummars@mail.nih.gov United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office (888) NCI-1937 United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030-4096 Canada, Ontario Princess Margaret Cancer Center Recruiting Toronto, Ontario, Canada, M5G2M9 收起 <<
NCT00423332	-		Completed	-	-
NCT00981721	Advanced Solid Malignancies	Phase 1	Completed	-	China, Beijing ... 展开 >> Research Site Beijing, Beijing, China China, Hong Kong Research Site Hong Kong, Hong Kong, China 收起 <<
NCT00750841	Solid Tumors	Phase 1	Active, not recruiting	December 31, 2018	Canada, Alberta ... 展开 >> Research Site Edmonton, Alberta, Canada, T6G 1Z5 Canada, Quebec Research Site Montreal, Quebec, Canada, H3T 1E2 United Kingdom Research Site Dundee, United Kingdom, DD1 9SY Research Site Glasgow, United Kingdom, G12 0YN Research Site London, United Kingdom, NW1 2PG Research Site London, United Kingdom, SE1 9RT 收起 <<
NCT01262612	Malignant Ascites ... 展开 >> Malignant Pleural Effusion 收起 <<	Phase 2	Terminated	-	Netherlands ... 展开 >> University Medical Centre Nijmegen Nijmegen, Gelderland, Netherlands, 6500 HB 收起 <<
NCT00532194	Ovarian Cancer	Phase 3	Unknown	December 2016	United Kingdom ... 展开 >> University College London London, Greater London, United Kingdom, WC1E 6BT 收起 <<
NCT02340611	Ovarian Cancer	Phase 2	Completed	-	Canada, Ontario ... 展开 >> Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00750425	Advanced Solid Tumors	Phase 1	Completed	-	Canada ... 展开 >> Research Site Hamilton, Canada Research Site Toronto, Canada Research Site Vancouver, Canada Denmark Research Site Herlev, Denmark Research Site Kobenhavn, Denmark 收起 <<

西地尼布 /Cediranib {[allProObj[0].p_purity_real_show]}

Cediranib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Cediranib 质控信息

Cediranib 生物活性

Cediranib 细胞研究

Cediranib 动物研究

Cediranib 临床研究

Cediranib 实验方案

Cediranib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

VEGFR1	VEGFR1/FLT1, IC50:5 nM
VEGFR3	VEGFR3/FLT4, IC50:<=3 nM
VEGFR2	VEGFR2/KDR, IC50:0.5 nM

西地尼布 /Cediranib {[allProObj[0].p_purity_real_show]}

Cediranib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Cediranib 质控信息

Cediranib 生物活性

Cediranib 细胞研究

Cediranib 动物研究

Cediranib 临床研究

Cediranib 实验方案

Cediranib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Cediranib 纯度/质量文件产品仅供科研